Sagimet Biosciences (SGMT) Competitors $4.76 +0.26 (+5.78%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SGMT vs. HUMA, ABVX, ORGO, ATXS, CRVS, IGMS, SANA, PRTC, MREO, and GLUEShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Humacyte (HUMA), ABIVAX Société Anonyme (ABVX), Organogenesis (ORGO), Astria Therapeutics (ATXS), Corvus Pharmaceuticals (CRVS), IGM Biosciences (IGMS), Sana Biotechnology (SANA), PureTech Health (PRTC), Mereo BioPharma Group (MREO), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Humacyte ABIVAX Société Anonyme Organogenesis Astria Therapeutics Corvus Pharmaceuticals IGM Biosciences Sana Biotechnology PureTech Health Mereo BioPharma Group Monte Rosa Therapeutics Sagimet Biosciences (NASDAQ:SGMT) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk. Which has more risk & volatility, SGMT or HUMA? Sagimet Biosciences has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Do insiders and institutionals have more ownership in SGMT or HUMA? 87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 17.6% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 11.2% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to SGMT or HUMA? In the previous week, Humacyte had 35 more articles in the media than Sagimet Biosciences. MarketBeat recorded 42 mentions for Humacyte and 7 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of -0.14 beat Humacyte's score of -0.16 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 3 Very Positive mention(s) 3 Positive mention(s) 27 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor SGMT or HUMA? Humacyte received 4 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.15% of users gave Sagimet Biosciences an outperform vote while only 63.04% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2596.15% Underperform Votes13.85%HumacyteOutperform Votes2963.04% Underperform Votes1736.96% Is SGMT or HUMA more profitable? Sagimet Biosciences' return on equity of -23.63% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% Humacyte N/A -942.81%-93.82% Do analysts rate SGMT or HUMA? Sagimet Biosciences currently has a consensus price target of $21.60, suggesting a potential upside of 353.78%. Humacyte has a consensus price target of $11.00, suggesting a potential upside of 144.99%. Given Sagimet Biosciences' higher possible upside, equities research analysts clearly believe Sagimet Biosciences is more favorable than Humacyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Humacyte 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, SGMT or HUMA? Sagimet Biosciences has higher revenue and earnings than Humacyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M73.01-$27.88MN/AN/AHumacyte$1.57M359.94-$110.78M-$1.34-3.35 SummarySagimet Biosciences beats Humacyte on 10 of the 15 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.01M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E RatioN/A11.10105.1417.83Price / Sales73.01362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book0.8610.377.096.50Net Income-$27.88M$153.60M$119.65M$226.22M7 Day Performance0.63%4.60%2.25%4.03%1 Month Performance-15.75%-6.29%-2.33%4.92%1 Year Performance29.35%33.41%33.98%29.30% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.1731 of 5 stars$4.76+5.8%$21.60+353.8%+29.3%$146.01M$2M0.008HUMAHumacyte2.8736 of 5 stars$4.38-0.7%$11.00+151.1%+76.1%$551.27M$1.57M0.00150Insider TradeNews CoverageABVXABIVAX Société Anonyme2.6874 of 5 stars$8.65-2.4%$39.80+360.1%-13.2%$547.46MN/A0.0061ORGOOrganogenesis4.1203 of 5 stars$4.02+1.3%$5.33+32.7%+56.4%$532.97M$433.14M-66.17950ATXSAstria Therapeutics1.8948 of 5 stars$9.41-1.8%$25.60+172.1%+117.3%$531.00MN/A-4.5030CRVSCorvus Pharmaceuticals2.7468 of 5 stars$9.01+9.3%$12.83+42.4%+534.8%$529.48MN/A-9.6930High Trading VolumeIGMSIGM Biosciences4.6736 of 5 stars$8.89-9.0%$16.13+81.4%+64.0%$528.60M$2.13M-2.44190Gap DownSANASana Biotechnology2.2051 of 5 stars$2.35-7.1%$13.50+474.5%-38.6%$524.68MN/A-1.68328PRTCPureTech Health1.8962 of 5 stars$21.78+0.4%$45.00+106.6%+7.1%$521.46M$3.33M0.00100Analyst RevisionNews CoverageMREOMereo BioPharma Group3.2316 of 5 stars$3.68+2.8%$7.50+103.8%+78.4%$516.16M$10M0.0040Analyst RevisionGLUEMonte Rosa Therapeutics3.0537 of 5 stars$8.35-0.1%$16.00+91.6%+184.9%$513.02MN/A-4.5690Positive News Related Companies and Tools Related Companies Humacyte Competitors ABIVAX Société Anonyme Competitors Organogenesis Competitors Astria Therapeutics Competitors Corvus Pharmaceuticals Competitors IGM Biosciences Competitors Sana Biotechnology Competitors PureTech Health Competitors Mereo BioPharma Group Competitors Monte Rosa Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SGMT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
